Builders FirstSource, Inc. BLDR

About Destiny Tech100

Destiny's flagship offering, the Destiny Tech100, will be a publicly-listed portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses.

Current Tech100 holdings include: SpaceX, OpenAI, Epic Games, Discord, Superhuman, and Stripe. For a comprehensive list of holdings, visit the fund website www.destiny.xyz/tech100.

Image for Press Release 1867753

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327776952/en/

The financial markets are complex and ever-changing, and it can be difficult to know where to start or what to do. This is where a professional can be invaluable. A professional will help a trader to understand the markets and develop a trading plan that is tailored to their individual needs and goals. They will provide advice and guidance on which markets to trade, which strategies to use, and when to buy and sell.In addition, a professional can offer support and feedback. Trading can be a lonely and isolating activity, so having someone to talk to about your trades and help you analyze your performance can be incredibly valuable.?Mrs Geneva JackHolloway on Facebook got on her knees and made me almost one million in one week.
Her WhatsApp +1(313) 205-0690

Wow guys i have a great opportunity and I didn't miss it, I gave a try about it, and I earn so much money with a expert trading platform name LARA KELLER on FACEBOOK I made over $36,432 with a investment of $8,543, so guys this is happiness to me and a Thanksgiving so give a try and so that you could make happiness to your self, you can click the link below ? to contact for more info

https://www.facebook.com/profile.php?id=100076456633939&mibextid=ZbWKwL

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.